Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,013 public trials 2,032 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

NCT00702052

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Mayo Clinic - Arizona Mayo Clinic - Scottsdale Multiple Locations, Arizona, United States
  • Highlands Oncology Group DeptofHighlandsOncologyGrp(2) Fayetteville, Arkansas, United States
  • Bay Area Cancer Research Dept.ofBayAreaCancerResearch Concord, California, United States
  • City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1) Duarte, California, United States
View all 31 locations
View Trial Details
Completed

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

NCT03239392

Conditions
CTCL, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • The James Cancer Center, Ohio State University Columbus, Ohio, United States
  • University of Virginia Cancer Center Charlottesville, Virginia, United States
View Trial Details
Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02596971

Conditions
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Rocky Mountain Cancer Center - Aurora Aurora, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • University Miami Miami, Florida, United States
  • New York Uni Medical Center New York, United States
View all 21 locations
View Trial Details
Completed

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

NCT02669017

Conditions
Blood Protein Disorders, Burkitt Lymphoma, Burkitt's Lymphoma, +39 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • Blood and Marrow Transplant Group of Georgia Atlanta, Georgia, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Completed

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

NCT01234766

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Maine Center for Cancer Medicine Scarborough, Maine, United States
  • Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States
  • Duke University Medical Center Durham, North Carolina, United States
  • Rhode Island Hospital Providence, Rhode Island, United States
View Trial Details

Related conditions